Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$33.16
-2.2%
$33.79
$29.31
$61.38
$3.96B0.61.51 million shs2.35 million shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.32
+0.1%
$12.39
$8.02
$15.78
$7.11B1.675.08 million shs5.61 million shs
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
$36.01
$35.96
$11.56
$36.09
$1.22B2.82171,367 shsN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$39.80
+0.1%
$33.97
$23.95
$52.34
$6.33B0.181.58 million shs2.48 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
0.00%+2.25%+7.38%-17.49%-38.80%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+6.32%+6.35%+36.53%-0.80%
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
0.00%0.00%0.00%0.00%0.00%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
0.00%+6.39%+18.31%+31.92%-16.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
4.2542 of 5 stars
4.52.00.04.62.30.80.0
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.3188 of 5 stars
1.34.00.00.32.01.71.3
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
N/AN/AN/AN/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
4.5371 of 5 stars
4.42.00.03.02.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.93
Moderate Buy$70.92113.88% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.50
Moderate Buy$15.175.95% Upside
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
0.00
N/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.72
Moderate Buy$57.8845.41% Upside

Current Analyst Ratings Breakdown

Latest IMGO, IONS, CYTK, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/26/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/12/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.00
6/9/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.00
5/29/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.00
5/20/2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/14/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/13/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$18.47M214.42N/AN/A($1.15) per share-28.83
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.60$2.26 per share6.34$12.33 per share1.16
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
N/AN/AN/AN/A$6.40 per shareN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$705M8.99N/AN/A$3.73 per share10.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7419.3416.082.808.43%7.54%3.57%8/6/2025 (Estimated)
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
-$42.31M-$1.84N/AN/AN/AN/A-31.85%-30.07%N/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)

Latest IMGO, IONS, CYTK, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
4/30/2025Q1 2025
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
N/AN/AN/AN/AN/A
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
5.99
5.99
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
N/A
13.15
13.16
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.63
9.66
9.62

Institutional Ownership

CompanyInstitutional Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
91.53%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
93.86%

Insider Ownership

CompanyInsider Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
3.40%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
14.90%
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million115.37 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Imago BioSciences, Inc. stock logo
IMGO
Imago BioSciences
2733.82 million28.78 millionNot Optionable
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
1,069159.16 million154.85 millionOptionable

Recent News About These Companies

Salanersen shines in early spinal muscular atrophy research

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$33.16 -0.75 (-2.21%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$32.50 -0.66 (-1.99%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.32 +0.02 (+0.10%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$14.53 +0.22 (+1.50%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Imago BioSciences stock logo

Imago BioSciences NASDAQ:IMGO

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Ionis Pharmaceuticals stock logo

Ionis Pharmaceuticals NASDAQ:IONS

$39.80 +0.02 (+0.05%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$40.35 +0.55 (+1.38%)
As of 04:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.